Summary
Thermo Fisher Scientific Inc. (TMO) reported a solid first quarter for 2018, with total revenues increasing by 23% year-over-year to $5.85 billion. This growth was driven by a combination of organic growth (7%), favorable currency translation ($209 million), and significant contributions from acquisitions, notably Patheon. The Laboratory Products and Services segment showed exceptional growth at 42%, largely due to recent acquisitions. Operating income rose 27% to $786 million, with an improved operating margin of 13.4% compared to 13.0% in the prior year quarter, reflecting strong execution and productivity improvements across most segments, although the Specialty Diagnostics and Laboratory Products and Services segments saw slight margin contractions. The company also provided an update on its financial position, highlighting a healthy cash balance of $950 million. Despite a decrease in cash flow from operations compared to the prior year, primarily due to working capital investments, management expressed confidence in its ability to meet short-term and long-term cash requirements. Key financial metrics indicate continued operational strength and strategic growth, supported by a robust business model across its diverse segments.
Financial Highlights
56 data points| Revenue | $5.85B |
| Cost of Revenue | $2.33B |
| Gross Profit | $2.58B |
| R&D Expenses | $234.00M |
| SG&A Expenses | $1.51B |
| Operating Expenses | $5.07B |
| Operating Income | $786.00M |
| Interest Expense | $163.00M |
| Net Income | $579.00M |
| EPS (Basic) | $1.44 |
| EPS (Diluted) | $1.43 |
| Shares Outstanding (Basic) | 402.00M |
| Shares Outstanding (Diluted) | 406.00M |
Key Highlights
- 1Total revenues increased by 23% to $5.85 billion in Q1 2018, up from $4.77 billion in Q1 2017, driven by organic growth, currency tailwinds, and acquisitions.
- 2Operating income grew by 27% to $786 million, with operating margin improving slightly to 13.4% from 13.0% in the prior year quarter.
- 3The Laboratory Products and Services segment experienced significant revenue growth of 42%, largely attributable to the acquisition of Patheon.
- 4Life Sciences Solutions segment revenues grew 10%, with operating income margin improving to 34.5% from 31.8%.
- 5Net income was $579 million, or $1.43 per diluted share, compared to $551 million, or $1.40 per diluted share, in the prior year quarter.
- 6As of March 31, 2018, the company had $950 million in cash and cash equivalents, and expressed confidence in its liquidity position.
- 7The company announced ongoing restructuring actions expected to result in additional charges of approximately $105 million in 2018 and 2019.